Many studies to date have shown an improvement in disease biomarkers during the course of low-dose IL-2 therapy, as measured by various scoring systems such as SLE responder index [100], disease activity score in psoriatic arthritis [97] and severity of alopecia tool [84], or metabolic parameters such as c-peptide decline in T1D [94] and liver enzyme and serum IgG levels in autoimmune hepatitis [87]. The gene discussed is IL2; the disease is type 1 diabetes mellitus.